PROGEN Share Price Performance
SEK 0.91
-24.59 (-96.42%)
Price SEK 0.91
Share PriceSEK 0.91
PROGEN Community Narratives
There are no narratives available yet.
Recent PROGEN News & Updates
No updates
Prostatype Genomics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 12, 2026
- Earnings per share (EPS)
- -1.22
- Gross Margin
- -2,948.25%
- Net Profit Margin
- -6,336.50%
- Debt/Equity Ratio
- 0%
Prostatype Genomics AB (publ) Competitors
About PROGEN
- Founded
- 2007
- Employees
- 6
- CEO
- WebsiteView website
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Swedish Market Performance
- 7 Days: 0.6%
- 3 Months: 3.8%
- 1 Year: 2.5%
- Year to Date: 0.7%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 3.1%. Similarly, the market is flat for the past 12 months. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading